Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: CYBERKEN who wrote (13331)	1/15/1998 10:23:00 AM
From: Andreas Helke	Read Replies (1) \| Respond to of 32384

I am not shure if it such a bad thing for the potential pharma parter to miss a Leptin deal with Ligand. The most impressive achievement of Leptin was to bring Ligand to its all time high in 1996. I would not complain if it did it again. I do now have 10 times as much shares than I had in summer 1996. Leptin development is a high risk gamble. First it is not yet known whether Leptin or Leptin level influencing compounds can be effective medicaments and second we don't know if Ligands development programs will be successful. If they are it will be a huge market. But I personnaly don't have much confidence about the eventual success of the Leptin development programs. Andreas